BOLT · Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics’ Q1 2026 results reflect a deliberate operational pivot following restructuring, with sharp declines in both R&D and G&A expenses—down 49% and 26% year-over-year, respectively—driven primarily by reduced salary and related costs. Collaboration revenue collapsed to $26,000 from $1.2 million, indicating minimal ongoing service-based income under existing partnerships, consistent with management’s focus on internal pipeline advancement over external monetization. The resulting net loss narrowed to $7.2 million (EPS $(4.31)) from $11.0 million (EPS $(5.76)), though this improvement stems almost entirely from cost discipline rather than revenue growth or margin expansion. Critically, the company reported $23.9 million in cash and marketable securities as of March 31, 2026—explicitly tied to funding operations into 2027 and completing the dose escalation portion of the BDC-4182 Phase 1/2 trial. This cash position anchors near-term viability and de-risks the upcoming Q3 2026 initial clinical data readout, which represents the first potential clinical validation of Bolt’s ISAC platform. Management emphasized encouragement from early BDC-4182 patient data and reiterated that CEA- and PD-L1-targeted ISAC programs remain on hold pending proof-of-concept from BDC-4182—underscoring that all future pipeline progression hinges on this single catalyst. With no new financing disclosed and minimal operating cash inflows, the company remains fully dependent on successful clinical execution and subsequent partnership or capital markets activity to advance beyond 2027.